Beneficial effects of fluvoxamine for hemiballism in a patient with depressive disorder: A case report

Acta Neurologica Belgica

Volumn 111, Issue 1, 2011, Pages 62-65

  Çayköylü, Ali ^a   Albayrak, Yakup ^a   Uǧurlu, Görkem Karakaş ^a   Ekinci, Okan ^a  

^a ATATURK TRAINING AND RESEARCH HOSPITAL   (Turkey)

Author keywords

[No Author keywords available]

Indexed keywords

BIPERIDEN; FLUVOXAMINE; HALOPERIDOL; ANTIDEPRESSANT AGENT;

ADULT; ARTICLE; BRIEF PSYCHIATRIC RATING SCALE; CASE REPORT; DRUG EFFECT; DRUG SUBSTITUTION; DRUG WITHDRAWAL; ELECTROENCEPHALOGRAM; EXTRAPYRAMIDAL SYMPTOM; HAMILTON SCALE; HEMIBALLISM; HUMAN; HYPERKINESIA; MAJOR DEPRESSION; MALE; MEDICAL EXAMINATION; NEUROLOGIC EXAMINATION; NUCLEAR MAGNETIC RESONANCE IMAGING; PHLEBOGRAPHY; PSYCHIATRIC DIAGNOSIS; TREATMENT RESPONSE; BRAIN; DEPRESSION; DYSKINESIA; MAGNETIC RESONANCE ANGIOGRAPHY; MIDDLE AGED; PATHOLOGY; RADIOGRAPHY;

ANTIDEPRESSIVE AGENTS, SECOND-GENERATION; BRAIN; DEPRESSIVE DISORDER; DYSKINESIAS; FLUVOXAMINE; HUMANS; MAGNETIC RESONANCE ANGIOGRAPHY; MAGNETIC RESONANCE IMAGING; MALE; MIDDLE AGED;

EID: 79955811841     PISSN: 03009009     EISSN: None     Source Type: Journal    
DOI: None     Document Type: Article

References (18)

1. Shannon KM. Hemiballismus. Clin Neuropharm. 1990; 13: 413-425.
2. Demssie YN, Kaushal K. Newly diagnosed type-2 diabetes mellitus presenting with hemichorea hemiballismus. J R Physicians Edinb. 2008; 38: 218-20.
3. Hyde TM., Hotson JR., Kleinman JE. Differential diagnosis of choreiform tardive dyskinesia. J Neuropsychiatry. 1991; 3: 255-268.
4. Furuse T, Hashimoto K. Fluvoxamine for blonanserinassociated akathisia in patients with schizophrenia: report of five cases. Ann Gen Psychiatry. 2010; 24: 9-17.
5. Furuse T, Hashimoto K. Fluvoxamine for aripiprazole-associated akathisia in patients with schizophrenias potential role of sigma-1 receptors. Ann Gen Psychiatry. 2010; 6: 9-11.
6. th ed., text revsion. Washington DC: American Psychiatric Assosiation. 2000.
7. Rossetti AO, Ghika JA, Vingerhoets F. et al. Neurogenic pain and abnormal movements contralateral to an anterior parietal artery stroke. Arch Neurol. 2003; 60: 1004-1006.
8. Guridi J, Obeso JA. The subthalamic nucleus, hemiballismus and Parkinson's disease: Reappraisal of a neurosurgical dogma. Brain. 2001; 124: 5-19.
9. Park SH, Kim YJ, Kim JM. et al. Oro-bucco linguial dyskinesia associated with nonketotic hyperglycaemia. J Clin Neurosci. 2006; 13: 947-9.
10. Bashir K, Manyam BV. Clozapine for the control of hemiballism. Clin Neuropharmacol. 1994; 17: 477-480.
11. Kenney C, Jankovic J. Tetrabenazine in the treatment of hyperkineticmovement disorders. Expert Rev Neurotherapeutics. 2006; 6: 7-17.
12. Hashimoto K, Ishiwata K. Sigma receptor ligands: possible application as therapeutic drugs and as radiopharmaceuticals. Curr Pharm Des. 2006; 12(30): 3857-76.
13. Hayashi T, Su TP. Sigma-1 receptor chaperones at the ER-mitochondrion interface regulate Ca(2+) signaling and cell survival. Cell. 2007; 131(3): 596-610.
14. Ishikawa M, Ishikawa M, Ishii K et al. High occupancy of sigma-1 receptors in the human brain after single oral administration of fluvoxamine: a positron emission tomography study using [11C]SA4503. Biol Psychiatry. 2007; 62(8): 878-83.
15. Gudelsky GA. Effects of sigma receptor ligands on the extracellular concentration of dopamine in the striatum and prefrontal cortex of the rat. Eur J Pharmacol. 1995;24:223-8.
16. Bastianetto S, Rouquier L, Perrault L, Aanger DJ. DTG-induced circling behaviour in rats may involve the interaction between sigma sites and nigro-striatal dopaminergic pathways. Neuropharmacogy. 1995; 34(3): 281-7.
17. Alonso G, Phan V, Guillemain I. et al. Immunocytochemical localization of the sigma (1) receptor in the adult rat central nervous system. Nuroscience. 2000; 97(1): 155-70.
18. Fahert CJ, Harkin AJ, Leonard BE. The functional sensitisation of sigma receptors following chronic selective serotonin reuptake inhibitor treatment. Eur J Pharmacol. 1998; 346(1): 15-21.